(NASDAQ: ENLV) Enlivex's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Enlivex's earnings in 2026 is $1,235,528,000.On average, 3 Wall Street analysts forecast ENLV's earnings for 2026 to be -$19,370,330, with the lowest ENLV earnings forecast at -$18,610,709, and the highest ENLV earnings forecast at -$19,940,046. On average, 3 Wall Street analysts forecast ENLV's earnings for 2027 to be -$21,791,622, with the lowest ENLV earnings forecast at -$20,937,048, and the highest ENLV earnings forecast at -$22,432,552.
In 2028, ENLV is forecast to generate -$227,601,380 in earnings, with the lowest earnings forecast at -$218,675,836 and the highest earnings forecast at -$234,295,539.